{"id":"W3009513461","doi":"10.1200/jco.2007.25.18_suppl.5519","title":"CA-125 response as a marker of clinical benefit in patients with recurrent ovarian cancer treated with gemcitabine and sorafenib—A trial of the PMH Phase II Consortium","year":2007,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Ovarian cancer diagnosis and treatment","field":"Medicine","cited_by":15,"is_retracted":false,"has_abstract":true,"ca_institutions":"Juravinski Cancer Centre","funders":"","keywords":"Medicine; Gemcitabine; Sorafenib; Clinical endpoint; Internal medicine; Response Evaluation Criteria in Solid Tumors; Oncology; Surrogate endpoint; Phases of clinical research; Ovarian cancer; Chemotherapy; Progression-free survival; Clinical trial; Cancer; Gastroenterology; Surgery; Hepatocellular carcinoma","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.002787785,0.0009134806,0.001921704,0.0004231657,0.0003092943,0.0007752403,0.0005631945,0.0009222202,0.002006381],"category_scores_gemma":[0.001509181,0.0004766024,0.0008144015,0.0004186987,0.0006205101,0.0005009797,0.0004093953,0.002069806,0.0002370772],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.001092363,"about_ca_system_score_gemma":0.001207681,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.0007076855,"about_ca_topic_score_gemma":0.001257523,"domain_scores_codex":[0.9992861,0.000463419,0.00004204317,0.00008326636,0.0000605099,0.00006466585],"domain_scores_gemma":[0.9991614,0.0001916275,0.0002080759,0.00004525279,0.00003406153,0.000359607],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"nonrandomized_trial","study_design_scores_codex":[0.8705483,0.01324372,0.02057187,0.0004361301,0.001036812,0.000157322,0.0001691493,0.001469821,0.01067806,0.0001412465,0.002210755,0.07933675],"study_design_scores_gemma":[0.676225,0.2743135,0.04220192,0.00003716455,0.0006777283,0.0002570402,0.00004204306,0.002664849,0.001719567,0.0001581354,0.001677012,0.00002609153],"study_design_candidate":"nonrandomized_trial","study_design_consensus":null,"genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9960891,0.001687947,0.0001754111,0.0003297176,0.00005168203,0.000778009,0.0002335383,0.00003037899,0.0006242032],"genre_scores_gemma":[0.9963487,0.0006254721,0.0006571224,0.0003614227,0.0002031522,0.0007188416,0.0005931742,0.000008368826,0.0004836353],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.002787785,"threshold_uncertainty_score":0.01474339,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.07201841788440105,"score_gpt":0.4603470873534958,"score_spread":0.3883286694690948,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}